Despite decades of clinical trials, no medication has received regulatory approval specifically for treating cocaine use disorder.1PubMed Central. New medications for the treatment of cocaine dependence That gap has driven researchers toward a wide range of pharmacological, behavioral, and technological strategies, some of which have produced genuinely encouraging results in recent years. The landscape includes everything from repurposed stimulants and psychedelic-assisted therapy to cocaine-destroying enzymes and brain stimulation, and the evidence behind each varies enormously.
Prescription Stimulants as Substitution Therapy
The logic here mirrors methadone for opioid addiction: give a controlled, longer-acting drug that occupies the same brain pathways cocaine targets, reducing cravings and the reinforcing rush of cocaine itself. A review of 38 randomized trials found that prescription psychostimulants promoted sustained abstinence and reduced cocaine use in people with cocaine use disorder.2PubMed Central. Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach Prescription amphetamines in particular performed well: a meta-analysis reported that they roughly doubled the likelihood of sustained abstinence and produced more cocaine-negative urine samples compared with placebo.3PubMed. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis Higher doses tended to work better than lower ones, which makes pharmacological sense if the goal is to adequately occupy dopamine pathways.
The approach is not without controversy. Prescribing one stimulant to treat addiction to another raises obvious concerns about diversion and misuse. Long-acting formulations help reduce that risk because they produce a slow, steady rise in brain dopamine rather than the sharp spike that makes cocaine reinforcing. Still, this strategy has gained enough traction that researchers now consider long-acting amphetamine formulations among the most promising pharmacological options for cocaine use disorder.
Ketamine-Assisted Treatment
Ketamine has attracted attention across psychiatry for its rapid-onset antidepressant effects, and researchers have begun testing whether those properties translate to addiction treatment. A randomized clinical trial compared a single ketamine infusion (paired with mindfulness-based behavioral therapy) against a single dose of midazolam, a sedative used as an active placebo. About 48% of participants in the ketamine group stayed abstinent over the final two weeks of the trial, compared with roughly 11% in the midazolam group. The ketamine group was also 53% less likely to relapse and reported craving scores nearly 60% lower throughout the study.4PubMed. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial
An earlier study found that a single sub-anesthetic ketamine infusion sharply increased motivation to change cocaine use and decreased cue-induced craving by about 60% from baseline values.5PubMed Central. The effects of sub-anesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine dependent research volunteers What makes ketamine interesting beyond the numbers is the proposed mechanism: rather than simply dampening reward circuits, ketamine may open a window of heightened neuroplasticity during which behavioral interventions like mindfulness training can take hold more effectively. The pairing of a pharmacological agent with structured therapy is a theme that runs through several of the more successful approaches to cocaine use disorder.
Psilocybin-Assisted Therapy
Psilocybin, the active compound in psychedelic mushrooms, has also entered clinical testing for cocaine dependence. A randomized trial of 40 participants found that those receiving psilocybin alongside therapy reported substantially more cocaine-free days than placebo recipients. About 30% of the psilocybin group achieved complete abstinence from cocaine through 180 days of follow-up, while none of the placebo participants did. The psilocybin group also showed a markedly lower risk of lapsing back into cocaine use over time.6JAMA Network Open. Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial
These are striking numbers, but the trial was small and the confidence intervals wide. Psilocybin-assisted therapy also requires specialized clinical settings, trained therapists, and careful screening for psychiatric conditions that could worsen with psychedelic exposure. The field is watching closely to see whether larger trials replicate these early signals.
Modafinil
Modafinil, a wakefulness-promoting drug prescribed for narcolepsy and sleep disorders, acts on the dopamine transporter but in a slower, milder way than cocaine. A clinical trial found that modafinil at 200 mg increased the maximum number of consecutive cocaine-free days and reduced craving in people with cocaine dependence.7PubMed Central. Modafinil for the treatment of cocaine dependence Animal research has added detail to the picture, showing that modafinil blocked the reinstatement of cocaine-seeking behavior through a glutamate-dependent mechanism in the brain’s reward circuitry.8PubMed Central. Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors
Modafinil’s appeal is partly practical: it is already widely available, has a relatively mild side-effect profile, and carries lower misuse potential than amphetamines. Its effects on cocaine use have been modest in trials, though, and it appears most useful as one component of a broader treatment strategy rather than a standalone solution.
N-Acetylcysteine and the Glutamate Pathway
Chronic cocaine use disrupts the brain’s glutamate balance, and that disruption is closely tied to relapse. N-acetylcysteine (NAC), a supplement widely available over the counter, works by restoring normal glutamate levels. In cocaine-dependent patients, an imaging study confirmed that NAC treatment normalized glutamate concentrations, and animal research showed that correcting this imbalance prevented relapse to drug-seeking behavior.9PubMed Central. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study
NAC is inexpensive and well-tolerated, which makes it attractive for widespread use. The clinical results in humans have been uneven, however. Some trials show reduced craving and cocaine use, while others show little effect. NAC may work best in combination with other interventions rather than alone, and the timing of treatment relative to active use may matter. The glutamate mechanism it targets is real and well-documented, but translating that into consistent clinical outcomes has proven difficult.
Contingency Management
Not every effective strategy for cocaine use disorder involves a pill or an infusion. Contingency management, which offers tangible rewards for drug-free urine tests, has some of the strongest evidence of any treatment approach. The concept is simple: meet your treatment goals and you earn vouchers redeemable for goods and services, or cash-based rewards, or chances at prizes. A study comparing cash-based reinforcement to the more traditional voucher system found that cash was just as effective as vouchers and did not increase drug cravings or high-risk behaviors.10PubMed Central. Contingency management for cocaine treatment: cash vs. vouchers
The size of the reward matters. A study testing prize-based contingency management found that patients in the higher-value condition achieved more abstinence, and the effect was strongest in patients who entered treatment with positive urine results, meaning those with the most severe use patterns.11PubMed Central. Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Despite strong evidence, contingency management remains underused in clinical practice, partly because of funding constraints and partly because of cultural resistance to the idea of “paying people not to use drugs.” That resistance is unfortunate, because for cocaine use disorder specifically, contingency management often outperforms pharmacological approaches that are accepted without question.
Transcranial Magnetic Stimulation
Repetitive transcranial magnetic stimulation (rTMS) uses magnetic pulses aimed at specific brain regions to alter neural activity non-invasively. For cocaine use disorder, most research has focused on stimulating the dorsolateral prefrontal cortex, a region involved in impulse control and decision-making that tends to function abnormally in people with addiction. A systematic review found that high-frequency rTMS applied to the left side of this region reduced cocaine use and craving, with possible additional benefits for depression and insomnia.12PubMed Central. Transcranial Magnetic Stimulation for the Treatment of Cocaine Addiction: A Systematic Review
A pilot study comparing rTMS on the left prefrontal cortex against standard pharmacological treatment over 29 days found significantly more cocaine-free urine tests and lower craving in the rTMS group.13PubMed Central. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study Interestingly, stimulating the right side of the same region also reduced craving in a separate study, though the effect disappeared after about four hours.14PubMed. One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving The evidence is still considered low quality overall because the existing studies are small and use varying protocols. But the approach is promising enough that larger controlled trials are underway.
Cocaine Vaccines and Cocaine-Destroying Enzymes
Rather than targeting the brain’s reward system, some researchers have tried to stop cocaine from reaching the brain at all. A cocaine vaccine tested in mice generated a strong, long-lasting antibody response and measurably decreased the amount of cocaine reaching the brain within seconds of injection.15Nature Medicine. Efficacy of a therapeutic cocaine vaccine in rodent models The idea is that antibodies bind to cocaine molecules in the bloodstream, making them too large to cross into the brain. Human trials of cocaine vaccines have been less impressive, with antibody levels varying widely between individuals and only a subset of participants achieving high enough levels to block cocaine’s effects.
A parallel strategy uses engineered enzymes that chew up cocaine before it can act. Researchers have developed a bacterial enzyme (cocaine esterase, or CocE) that rapidly and specifically breaks down cocaine. The native enzyme was unstable at body temperature, but protein engineering substantially improved its stability, making it a viable candidate for treating cocaine overdose and, potentially, addiction.16PubMed Central. Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction Another team engineered a version of human butyrylcholinesterase fused with human serum albumin that prevented seizures in rats given normally lethal cocaine doses and blocked cocaine-triggered relapse to drug-seeking behavior.17Neuropsychopharmacology. A Cocaine Hydrolase Engineered from Human Butyrylcholinesterase Selectively Blocks Cocaine Toxicity and Reinstatement of Drug Seeking in Rats Further work showed that a rationally designed version of this enzyme could break down not only cocaine itself but also its major metabolite, benzoylecgonine.18PubMed Central. Metabolic Enzymes of Cocaine Metabolite Benzoylecgonine
These biological approaches are conceptually elegant but face real hurdles. Vaccines require a robust immune response that not everyone mounts equally. Enzyme therapies require repeated dosing and are expensive to produce. Neither approach addresses the psychological and behavioral dimensions of addiction. Still, they offer something no other strategy does: the ability to render cocaine pharmacologically inert in the body.
Ibogaine
Ibogaine, a psychoactive alkaloid derived from an African shrub, has a decades-long underground reputation as an addiction interrupter. A meta-analysis of animal studies found that ibogaine treatment lowered the cocaine-induced dopamine surge in brain reward areas, which is one plausible mechanism for reducing cocaine’s reinforcing effects.19Translational Psychiatry. Ibogaine and addiction in the animal model, a systematic review and meta-analysis A review of ibogaine’s pharmacology concluded that both ibogaine and its main metabolite modulate multiple receptor systems simultaneously, and that this broad action across pathways may be responsible for its reported anti-addictive properties.20PubMed. Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview
The problem with ibogaine is safety. It can cause dangerous heart rhythm disturbances, and several deaths have been reported in unregulated treatment settings. It is classified as a controlled substance in many countries and is not available through legal medical channels in the United States. Some clinics operate in countries where ibogaine is unregulated, but the lack of standardized dosing, medical screening, and cardiac monitoring makes this a genuinely risky option. Research into noribogaine and synthetic analogs that retain the therapeutic properties while reducing cardiac risk is ongoing.
Approaches That Have Disappointed
Not every strategy that looked good in theory has survived contact with clinical data. Baclofen, a muscle relaxant that enhances GABA signaling, was tested in a multi-center trial for cocaine dependence and failed to increase cocaine-free days compared to placebo by any measure.21PubMed Central. Multi-Center Trial of Baclofen for Abstinence Initiation in Severe Cocaine Dependent Individuals Lorcaserin, a serotonin receptor agonist originally approved for weight loss, reduced cocaine self-administration in rats but had the opposite of the desired effect in a small human trial: participants given lorcaserin chose cocaine more often, not less, in laboratory choice sessions.22PubMed Central. Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial These outcomes are a useful reminder that animal models, while valuable, do not always predict human results, especially for a condition as psychologically complex as cocaine addiction.
Cannabidiol (CBD) has generated popular interest as a treatment for nearly everything, cocaine addiction included. A systematic review found that CBD altered contextual memory associated with cocaine and reduced some cocaine-induced harms like seizures and liver damage in animal models.23PubMed. Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review But when tested more specifically, CBD did not affect the reconsolidation of cocaine-associated memories, the rate at which cocaine memories extinguished, or drug-primed reinstatement of cocaine preference in mice.24PubMed. Cannabidiol (CBD) reduces cocaine-environment memory in mice The gap between CBD’s general neuroprotective properties and any specific anti-cocaine effect remains wide.
Combination Strategies and Personalized Treatment
Given that no single agent has proven consistently effective, researchers have increasingly looked at combining medications. A review of pharmacotherapeutic strategies identified positive signals for several agents used individually and flagged the combination of topiramate with extended-release mixed amphetamine salts as a promising pairing.25Addiction. Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer? The logic is that different drugs address different aspects of the disorder: one might reduce craving while another improves impulse control or normalizes disrupted neurotransmitter systems.
Pharmacogenomics offers another layer. Not everyone with cocaine use disorder responds to the same medication, and genetic variation helps explain why. Research has shown that genetic differences in the dopamine transporter influence how well patients respond to disulfiram, an older drug sometimes used off-label for cocaine dependence. Patients with genetically higher dopamine transporter levels had better outcomes with disulfiram treatment.26PubMed Central. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction Similar genetic considerations apply to methylphenidate therapy, where variations in transporter genes may predict who benefits most.27PubMed Central. Pharmacogenetic Treatments for Drug Addiction: Cocaine, Amphetamine and Methamphetamine The idea of matching a patient’s genetic profile to the treatment most likely to work for them is still largely aspirational, but the groundwork is being laid.
Ibudilast and Neuroinflammation
A newer line of research targets neuroinflammation, which chronic cocaine use promotes. Ibudilast, an anti-inflammatory drug already used in some countries for asthma and post-stroke dizziness, reduced cocaine self-administration in rats across multiple dosing schedules and blocked both cocaine-primed and cue-triggered relapse to drug seeking. At a cellular level, ibudilast strengthened inhibitory signaling in reward circuits that cocaine had weakened, helping restore the brain’s normal excitation-to-inhibition balance.28PubMed Central. Ibudilast attenuates cocaine self-administration and prime- and cue-induced reinstatement of cocaine seeking in rats Human trials are needed before any conclusions can be drawn, but the strategy of treating addiction as partly an inflammatory disorder opens a fundamentally different treatment angle.
Deep Brain Stimulation
At the most invasive end of the spectrum sits deep brain stimulation (DBS), which involves surgically implanting electrodes in specific brain structures. The nucleus accumbens, a key hub in the brain’s reward circuitry, is the primary target. DBS in this region has shown promising effects on addiction-related behaviors in both animal models and a small number of human case reports.29PubMed Central. Deep Brain Stimulation in Drug Addiction Treatment: Research Progress and Perspective The procedure is currently reserved for severe, treatment-resistant cases and remains highly experimental for addiction. Ethical questions about implanting brain electrodes to treat a behavioral condition are significant, and long-term outcomes data are essentially nonexistent for this application.
The Danger of Illicit Substitutes
While researchers work to develop medical treatments, some people who use cocaine turn to illicit alternatives on their own. Synthetic cathinones, sold as “bath salts” or under constantly shifting brand names, are designer drugs specifically engineered to mimic the effects of cocaine, amphetamines, and ecstasy while circumventing drug laws.30PubMed Central. Psychoactive Bath Salts and Neurotoxicity Risk These substances carry serious neurotoxicity risks, and because their chemical structures are constantly being tweaked to stay ahead of regulations, users often have no idea what they are actually consuming. Emergency room presentations involving synthetic cathinones frequently include agitation, psychosis, hyperthermia, and cardiovascular emergencies. Replacing cocaine with an unregulated cathinone is not harm reduction; it is trading a known danger for an unknown one.